• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kezar Life Sciences Inc.

    3/21/25 5:54:29 PM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Kezar Life Sciences Inc

    (Name of Issuer)


    COMMON-STOCK

    (Title of Class of Securities)


    49372L100

    (CUSIP Number)


    09/30/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    49372L100


    1Names of Reporting Persons

    Barclays PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    7Sole Dispositive Power

    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12Type of Reporting Person (See Instructions)



    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kezar Life Sciences Inc
    (b)Address of issuer's principal executive offices:

    4000 Shoreline Court
    Item 2. 
    (a)Name of person filing:

    Barclays PLC
    (b)Address or principal business office or, if none, residence:

    1 Churchill Place, London - E14 5HP
    (c)Citizenship:

    X0
    (d)Title of class of securities:

    COMMON-STOCK
    (e)CUSIP No.:

    49372L100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Barclays PLC
     
    Signature:Ramya Rao
    Name/Title:Director
    Date:03/21/2025
    Get the next $KZR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KZR

    DatePrice TargetRatingAnalyst
    8/11/2023$4.00Overweight → Equal Weight
    Wells Fargo
    3/16/2023Outperform → Mkt Perform
    William Blair
    12/8/2021$19.00Overweight
    Wells Fargo
    11/16/2021$12.00 → $20.00Buy
    HC Wainwright & Co.
    7/20/2021$14.00Buy
    JonesTrading
    More analyst ratings

    $KZR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage

      5/28/25 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH. Additionally, the event will feature presentations from Craig Lammert, MD, Associate Professor of

      3/24/25 8:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kezar Life Sciences Inc.

      10-Q - Kezar Life Sciences, Inc. (0001645666) (Filer)

      5/13/25 4:11:25 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

      5/13/25 4:05:48 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Kezar Life Sciences Inc.

      DEFA14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:12:43 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kezar Life Sciences downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

      8/11/23 7:45:02 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences downgraded by William Blair

      William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

      3/16/23 7:29:33 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kezar Life Sciences with a new price target

      Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00

      12/8/21 7:24:52 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care